Genomics Research Center, Academia Sinica, 128, Academia Rd., Sec. 2, Nankang, Taipei, 115, Taiwan.
Cancer Res. 2013 Aug 1;73(15):4711-21. doi: 10.1158/0008-5472.CAN-12-3165. Epub 2013 May 30.
The retinoblastoma binding protein RBP2 (KDM5A) is a histone demethylase that promotes gastric cancer cell growth and is enriched in drug-resistant lung cancer cells. In tumor-prone mice lacking the tumor suppressor gene RB or MEN1, genetic ablation of RBP2 can suppress tumor initiation, but the pathogenic breadth and mechanistic aspects of this effect relative to human tumors have not been defined. Here, we approached this question in the context of lung cancer. RBP2 was overexpressed in human lung cancer tissues where its depletion impaired cell proliferation, motility, migration, invasion, and metastasis. RBP2 oncogenicity relied on its demethylase and DNA-binding activities. RBP2 upregulated expression of cyclins D1 and E1 while suppressing the expression of cyclin-dependent kinase inhibitor p27 (CDKN1B), each contributing to RBP2-mediated cell proliferation. Expression microarray analyses revealed that RBP2 promoted expression of integrin-β1 (ITGB1), which is implicated in lung cancer metastasis. Mechanistic investigations established that RBP2 bound directly to the p27, cyclin D1, and ITGB1 promoters and that exogenous expression of cyclin D1, cyclin E1, or ITGB1 was sufficient to rescue proliferation or migration/invasion, respectively. Taken together, our results establish an oncogenic role for RBP2 in lung tumorigenesis and progression and uncover novel RBP2 targets mediating this role.
视网膜母细胞瘤结合蛋白 RBP2(KDM5A)是一种组蛋白去甲基酶,可促进胃癌细胞生长,并在耐药性肺癌细胞中富集。在缺乏肿瘤抑制基因 RB 或 MEN1 的易患肿瘤的小鼠中,RBP2 的基因缺失可以抑制肿瘤起始,但相对于人类肿瘤,尚未确定这种效应的发病广度和机制方面。在这里,我们在肺癌的背景下探讨了这个问题。RBP2 在人类肺癌组织中过表达,其缺失会损害细胞增殖、运动性、迁移、侵袭和转移。RBP2 的致癌性依赖于其去甲基酶和 DNA 结合活性。RBP2 上调了细胞周期蛋白 D1 和 E1 的表达,同时抑制了细胞周期蛋白依赖性激酶抑制剂 p27(CDKN1B)的表达,这两者都有助于 RBP2 介导的细胞增殖。表达微阵列分析显示,RBP2 促进了整合素-β1(ITGB1)的表达,ITGB1 参与了肺癌转移。机制研究表明,RBP2 直接结合到 p27、细胞周期蛋白 D1 和 ITGB1 启动子上,并且外源性表达细胞周期蛋白 D1、细胞周期蛋白 E1 或 ITGB1 足以分别挽救增殖或迁移/侵袭。总之,我们的研究结果确立了 RBP2 在肺肿瘤发生和进展中的致癌作用,并揭示了介导这种作用的新的 RBP2 靶标。